Change over period
From:
To:
Zoom:
- 1Y
- 3Y
- 5Y
- 10Y
- 15Y
- 20Y
- Max
Cyclo Therapeutics Inc
NASDAQ CYTH
Data sourced from
and
and
Cyclo Therapeutics Inc Non-Cash Items (Other) 2 year CAGR for the Trailing 12 Months (TTM) ending March 31, 2024
Cyclo Therapeutics Inc Non-Cash Items (Other) 2 year CAGR is NA for the Trailing 12 Months (TTM) ending March 31, 2024. Non-Cash Items (Other) are non-cash expenses or gains that impact a company's financial statements, excluding depreciation and amortization. CAGR, or the Compound Annual Growth Rate, quantifies the mean annual growth rate of an investment or financial metric over a specified time span, considering the influence of compounding. It is instrumental in determining the true annualized return on an investment.
-
Cyclo Therapeutics Inc Non-Cash Items (Other) for the Trailing 12 Months (TTM) ending March 31, 2023 was USD -30.73 K, a 99.10% change year over year.
-
Cyclo Therapeutics Inc Non-Cash Items (Other) for the Trailing 12 Months (TTM) ending March 31, 2022 was USD -3.41 M, a 28.31% change year over year.
-
Cyclo Therapeutics Inc Non-Cash Items (Other) for the Trailing 12 Months (TTM) ending March 31, 2021 was USD -4.76 M, a -10,815.03% change year over year.
-
Cyclo Therapeutics Inc Non-Cash Items (Other) for the Trailing 12 Months (TTM) ending March 31, 2020 was USD 44.45 K, a -42.43% change year over year.
Don’t Miss A Beat
Looking to stay ahead of the competition and stay informed? Receive your daily dose of market news, trends, and analysis to kickstart your day and stay up-to-date.
NASDAQ: CYTH
| CEO | Mr. N. Scott Fine |
| IPO Date | Feb. 23, 2011 |
| Location | United States |
| Headquarters | 6714 NW 16th Street, Gainesville, FL, United States, 32653 |
| Employees | 8 |
| Sector | Healthcare |
| Industry | Drug manufacturers - specialty & generic |
Description
Cyclo Therapeutics, Inc., a clinical stage biotechnology company, engages in the development of cyclodextrin-based products for the treatment of neurodegenerative diseases. The company's lead drug candidate is Trappsol Cyclo (hydroxypropyl beta cyclodextrin), an orphan drug, which is in Phase III clinical trials for the treatment of Niemann-Pick Type C disease; and in Phase IIb clinical trials for the treatment of Alzheimer's disease. It also sells cyclodextrins and related products to the pharmaceutical, nutritional, and other industries, primarily for use in diagnostics and specialty drugs. The company was formerly known as CTD Holdings, Inc. and changed its name to Cyclo Therapeutics, Inc. in September 2019. Cyclo Therapeutics, Inc. was incorporated in 1990 and is headquartered in Gainesville, Florida.
Key trends
Similar companies
Phibro Animal Health Corporation
NA
NA
Eagle Pharmaceuticals Inc
NA
NA
StockViz Staff
September 20, 2024
Any question? Send us an email